ERBB2 and neoplasm: In light of preclinical studies demonstrating that tumor cells binding trastuzumab were more efficiently recognized by Her2 reactive T-cells [12], concomitant administration of trastuzumab and Her2 vaccines may cause substantial synergies and represents a promising treatment strategy.